Unlocking the potential of T cell engagers in solid tumors.

T cell engagers (TCEs) represent a targeted immunotherapy approach that is reshaping the cancer treatment landscape. While multiple TCEs are approved for the treatment of patients with hematologic malignancies, TCE development in solid tumors continues to face challenges including target heterogeneity within the tumor, an immunosuppressive microenvironment, on-target toxicity in normal tissues, and complex safety profiles. Target selection, creative protein engineering, and thoughtful clinical design are core principles that will guide future strategies for the next generation of TCE therapeutics.